These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
277 related items for PubMed ID: 18183478
1. Cell-specific delivery of a transforming growth factor-beta type I receptor kinase inhibitor to proximal tubular cells for the treatment of renal fibrosis. Prakash J, de Borst MH, van Loenen-Weemaes AM, Lacombe M, Opdam F, van Goor H, Meijer DK, Moolenaar F, Poelstra K, Kok RJ. Pharm Res; 2008 Oct; 25(10):2427-39. PubMed ID: 18183478 [Abstract] [Full Text] [Related]
2. Pirfenidone suppresses MAPK signalling pathway to reverse epithelial-mesenchymal transition and renal fibrosis. Li Z, Liu X, Wang B, Nie Y, Wen J, Wang Q, Gu C. Nephrology (Carlton); 2017 Aug; 22(8):589-597. PubMed ID: 27245114 [Abstract] [Full Text] [Related]
3. Intervention in growth factor activated signaling pathways by renally targeted kinase inhibitors. Fretz MM, Dolman ME, Lacombe M, Prakash J, Nguyen TQ, Goldschmeding R, Pato J, Storm G, Hennink WE, Kok RJ. J Control Release; 2008 Dec 18; 132(3):200-7. PubMed ID: 18793687 [Abstract] [Full Text] [Related]
4. The selective A3AR antagonist LJ-1888 ameliorates UUO-induced tubulointerstitial fibrosis. Lee J, Hwang I, Lee JH, Lee HW, Jeong LS, Ha H. Am J Pathol; 2013 Nov 18; 183(5):1488-1497. PubMed ID: 24001475 [Abstract] [Full Text] [Related]
8. Src inhibition blocks renal interstitial fibroblast activation and ameliorates renal fibrosis. Yan Y, Ma L, Zhou X, Ponnusamy M, Tang J, Zhuang MA, Tolbert E, Bayliss G, Bai J, Zhuang S. Kidney Int; 2016 Jan 18; 89(1):68-81. PubMed ID: 26444028 [Abstract] [Full Text] [Related]
10. Increasing cGMP-dependent protein kinase activity attenuates unilateral ureteral obstruction-induced renal fibrosis. Cui W, Maimaitiyiming H, Qi X, Norman H, Zhou Q, Wang X, Fu J, Wang S. Am J Physiol Renal Physiol; 2014 May 01; 306(9):F996-1007. PubMed ID: 24573388 [Abstract] [Full Text] [Related]
11. Imatinib-ULS-lysozyme: a proximal tubular cell-targeted conjugate of imatinib for the treatment of renal diseases. Dolman ME, van Dorenmalen KM, Pieters EH, Lacombe M, Pato J, Storm G, Hennink WE, Kok RJ. J Control Release; 2012 Feb 10; 157(3):461-8. PubMed ID: 21911014 [Abstract] [Full Text] [Related]
12. Transforming growth factor-β induces vascular endothelial growth factor-C expression leading to lymphangiogenesis in rat unilateral ureteral obstruction. Suzuki Y, Ito Y, Mizuno M, Kinashi H, Sawai A, Noda Y, Mizuno T, Shimizu H, Fujita Y, Matsui K, Maruyama S, Imai E, Matsuo S, Takei Y. Kidney Int; 2012 May 10; 81(9):865-79. PubMed ID: 22258325 [Abstract] [Full Text] [Related]
13. Blocking the class I histone deacetylase ameliorates renal fibrosis and inhibits renal fibroblast activation via modulating TGF-beta and EGFR signaling. Liu N, He S, Ma L, Ponnusamy M, Tang J, Tolbert E, Bayliss G, Zhao TC, Yan H, Zhuang S. PLoS One; 2013 May 10; 8(1):e54001. PubMed ID: 23342059 [Abstract] [Full Text] [Related]
14. Inhibition of ROCK2 alleviates renal fibrosis and the metabolic disorders in the proximal tubular epithelial cells. You R, Zhou W, Li Y, Zhang Y, Huang S, Jia Z, Zhang A. Clin Sci (Lond); 2020 Jun 26; 134(12):1357-1376. PubMed ID: 32490513 [Abstract] [Full Text] [Related]
15. MKP2 inhibits TGF-β1-induced epithelial-to-mesenchymal transition in renal tubular epithelial cells through a JNK-dependent pathway. Li Z, Liu X, Tian F, Li J, Wang Q, Gu C. Clin Sci (Lond); 2018 Nov 15; 132(21):2339-2355. PubMed ID: 30322849 [Abstract] [Full Text] [Related]
16. Opposite role of CD44-standard and CD44-variant-3 in tubular injury and development of renal fibrosis during chronic obstructive nephropathy. Rampanelli E, Rouschop KM, Claessen N, Teske GJ, Pals ST, Leemans JC, Florquin S. Kidney Int; 2014 Sep 15; 86(3):558-69. PubMed ID: 24717295 [Abstract] [Full Text] [Related]
17. Pterostilbene alleviates fructose-induced renal fibrosis by suppressing TGF-β1/TGF-β type I receptor/Smads signaling in proximal tubular epithelial cells. Gu TT, Chen TY, Yang YZ, Zhao XJ, Sun Y, Li TS, Zhang DM, Kong LD. Eur J Pharmacol; 2019 Jan 05; 842():70-78. PubMed ID: 30336139 [Abstract] [Full Text] [Related]
18. R-268712, an orally active transforming growth factor-β type I receptor inhibitor, prevents glomerular sclerosis in a Thy1 nephritis model. Terashima H, Kato M, Ebisawa M, Kobayashi H, Suzuki K, Nezu Y, Sada T. Eur J Pharmacol; 2014 Jul 05; 734():60-6. PubMed ID: 24726873 [Abstract] [Full Text] [Related]
19. Targeting of a platinum-bound sunitinib analog to renal proximal tubular cells. Dolman ME, Harmsen S, Pieters EH, Sparidans RW, Lacombe M, Szokol B, Orfi L, Kéri G, Storm G, Hennink WE, Kok RJ. Int J Nanomedicine; 2012 Jul 05; 7():417-33. PubMed ID: 22334775 [Abstract] [Full Text] [Related]
20. Inhibition of TGF-β1-receptor posttranslational core fucosylation attenuates rat renal interstitial fibrosis. Shen N, Lin H, Wu T, Wang D, Wang W, Xie H, Zhang J, Feng Z. Kidney Int; 2013 Jul 05; 84(1):64-77. PubMed ID: 23486519 [Abstract] [Full Text] [Related] Page: [Next] [New Search]